IL1B and COVID-19: Application of Canakinumab, a humanized monoclonal antibody against IL‐1β in a sub‐group of hospitalized patients with COVID‐19 and subsequent swift reduction in the systemic inflammatory response and oxygenation improvement by Claudio Ucciferri et al. also manifests the fundamental role of the immune system and inflammatory cytokines in the SARS‐CoV‐2 pathophysiology.65, 66